Friend us on facebook Become a fan on Facebook  
       

Contact Us Here:

first name
last name
phone
email
comments
 
 

The Myelin Project

P.O. Box 39,
Pacific Palisades,
CA  90272-0039

User Name:
Password:
Remember Login:
 
Forgot your password?
 
Or, to request a login for this site, click here.


January News


Myelin News


January 27th, 2012


Family of ALD sufferers pledge to raise money for The Myelin Project

  

   Two brothers are following in their father’s footsteps and becoming trustees of a global charity. Charles and Harry Fynn of Bournemouth have pledged to throw themselves into fundraising for The Myelin Project and to help raise awareness of its work. It is a cause close to their heart for a very good reason as both young men carry the rogue gene for ALD (adrenoleukodystrophy). It has been described as a “cerebral timebomb” which was once considered fatal. That was until the parents of an American sufferer, Lorenzo Odone, refused to accept the prognosis that there was no hope for their son. The outcome of their search for a cure was a special therapy that became known as Lorenzo’s Oil.   READ MORE...


January 23rd, 2012


Metabolites Involved in Chronic Pain
 
 A rendition of the bioinformatics analysis superimposed between two neurons. Combined with the METLIN metabolite database, the analysis ultimately revealed DMS as a naturally occurring metabolite and as an active molecule in chronic pain.Gary Siuzdak and Gary Patti

Untargeted metabolic profiling implicates a new suite of metabolites that may be involved in nerve damage-induced pain.

By Jeffrey M. Perkel | January 22, 2012

 

An analysis of the metabolic profile of a rat model of chronic pain has identified novel dysregulated metabolites that may underlie the condition, according to a study published today (January 22) in Nature Chemical Biology. If the results hold up in humans, one of these metabolites, which has not previously been associated with neuropathic pain, could potentially serve as both a molecular indicator of and therapeutic target for the condition, for which few treatment options exist.  Read more...

 

 

German Society for Gene Therapy "Perspective in Cell and Gene-Based Medicine" Congress, Frankfurt (Main) March 15th – 17th , 2012

 
 

January 20th, 2012


"The three-parent family: this is another attempt to dehumanise disabled people"

By   Last updated: January 20th, 2012
 

   

 

                     Lorenzo & Augusto Odone                                 Cristina Odone

Cristina Odone is a journalist, novelist and broadcaster specialising in the relationship between society, families and faith. She is a Research Fellow at the Centre for Policy Studies and is a former editor of the Catholic Herald and deputy editor of the New Statesman. She is married and lives in west London with her husband, two stepsons and a daughter. 

 
 

January 11th, 2012


The Promise and Peril of the Mass-Market Genome

 anImage

Posted 3:54PM 01/11/12Investing

 

The relentless march of genome sequencing technology continued this week, right on target. When I wrote aboutthe race to the $1,000 genomelate last year, I had no idea that the two largest sequencing companies would so soon unveil machines capable of offering just that, but I knew it was coming. Now that it's here, what does it mean for the future of medicine -- and the future of the planet? More than you might think.


(See full article from DailyFinance:http://srph.it/ACsUac)

January 6th, 2012


Gene therapy clinical trial for spinal muscular atrophy started

Isis Pharmaceuticals has announced that it has started a Phase 1 clinical trial of an antisense oligonucleotide drug called ISIS-SMNRx in patients with spinal muscular atrophy (SMA). This safety trial based in the USA will test the drug in 24 children with SMA.  Read More:  http://www.muscular-dystrophy.org/research/news/5025_gene_therapy_clinical_trial_for_spinal_muscular_atrophy_started